{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:43:14Z","timestamp":1773819794318,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 NS118337"],"award-info":[{"award-number":["R21 NS118337"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eplepsyres.2025.107712","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:55:36Z","timestamp":1763765736000},"page":"107712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Long-term administration of EQU-001 (ivermectin) suppresses spasms in a rat model of infantile epileptic spasms syndrome"],"prefix":"10.1016","volume":"219","author":[{"given":"Chian-Ru","family":"Chern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Schonwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Vel\u00ed\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libor","family":"Vel\u00ed\u0161ek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eplepsyres.2025.107712_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/epi.13783","article-title":"Neuroinflammatory targets and treatments for epilepsy validated in experimental models","volume":"58","author":"Aronica","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib2","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1007\/s10620-021-07258-x","article-title":"Anti-inflammatory effects of ivermectin in the treatment of acetic acid-induced colitis in rats: involvement of GABA(B) Receptors","volume":"67","author":"Aryannejad","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.nbd.2016.03.007","article-title":"Current understanding and neurobiology of epileptic encephalopathies","volume":"92","author":"Auvin","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107750","article-title":"Validated animal models for antiseizure drug (ASD) discovery: advantages and potential pitfalls in ASD screening","volume":"167","author":"Barker-Haliski","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib5","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s12035-018-1215-5","article-title":"Viral triggers and inflammatory mechanisms in pediatric epilepsy","volume":"56","author":"Bartolini","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib6","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1021\/acschemneuro.2c00783","article-title":"Structural elucidation of ivermectin binding to alpha7nAChR and the induced channel desensitization","volume":"14","author":"Bondarenko","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202000011","article-title":"Turning a drug target into a drug candidate: a new paradigm for neurological drug discovery?","volume":"42","author":"Buckingham","year":"2020","journal-title":"Bioessays"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib8","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1528-1167.2011.03220.x","article-title":"Validation of the rat model of cryptogenic infantile spasms","volume":"52","author":"Chachua","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib9","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1113\/JP275236","article-title":"Ivermectin and its target molecules: shared and unique modulation mechanisms of ion channels and receptors by ivermectin","volume":"596","author":"Chen","year":"2018","journal-title":"J. Physiol."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2019.03.004","article-title":"AQB-565 shows promise in preclinical testing in the model of epileptic spasms during infancy: Head-to-head comparison with ACTH","volume":"152","author":"Chern","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106950","article-title":"ACTON PROLONGATUM(R) suppresses spasms head to head with Acthar(R) Gel in the model of infantile spasms","volume":"105","author":"Chern","year":"2020","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s43440-022-00437-1","article-title":"Novel neurosteroid pregnanolone pyroglutamate suppresses neurotoxicity syndrome induced by tetramethylenedisulfotetramine but is ineffective in a rodent model of infantile spasms","volume":"75","author":"Chern","year":"2023","journal-title":"Pharm. Rep."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3349\/ymj.2008.49.1.1","article-title":"Role of brain inflammation in epileptogenesis","volume":"49","author":"Choi","year":"2008","journal-title":"Yonsei Med J."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib14","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0028-3908(86)90154-1","article-title":"Anticonvulsant effects of ivermectin in genetically-epileptic chickens","volume":"25","author":"Crichlow","year":"1986","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108371","article-title":"The anticonvulsant zonisamide positively modulates recombinant and native glycine receptors at clinically relevant concentrations","volume":"182","author":"Devenish","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib16","first-page":"303","article-title":"Ivermectin as an adjunct in the treatment of refractory epilepsy]. Rev Neurol","volume":"65","author":"Diazgranados-Sanchez","year":"2017"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cns.12371","article-title":"Inflammation and epilepsy in the developing brain: clinical and experimental evidence","volume":"21","author":"Dupuis","year":"2015","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00441-003-0751-z","article-title":"Development of the blood-brain barrier","volume":"314","author":"Engelhardt","year":"2003","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fnmol.2015.00055","article-title":"Functional characterization of ivermectin binding sites in alpha1beta2gamma2L GABA(A) receptors","volume":"8","author":"Estrada-Mondragon","year":"2015","journal-title":"Front Mol. Neurosci."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fphar.2017.00057","article-title":"Nicotine Elicits Convulsive Seizures by Activating Amygdalar Neurons","volume":"8","author":"Iha","year":"2017","journal-title":"Front Pharm."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib21","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s11064-022-03804-9","article-title":"Possible Interaction of Opioidergic and Nitrergic Pathways in the Anticonvulsant Effect of Ivermectin on Pentylenetetrazole-Induced Clonic Seizures in Mice","volume":"48","author":"Jourian","year":"2023","journal-title":"Neurochem. Res"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.bbr.2014.07.017","article-title":"Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia","volume":"272","author":"Karamihalev","year":"2014","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib23","article-title":"Ivermectin: A Multifaceted Drug With a Potential Beyond Anti-parasitic Therapy","author":"Kaur","year":"2024","journal-title":"Cureus 16 e56025"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/fcp.12902","article-title":"Evaluation of therapeutic potential of ivermectin against complete Freund's adjuvant-induced arthritis in rats: Involvement of inflammatory mediators","volume":"37","author":"Khan","year":"2023","journal-title":"Fundam. Clin. Pharm."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib25","first-page":"325","article-title":"Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications","volume":"15","author":"Kircik","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0278-6915(89)90048-3","article-title":"Effects of ivermectin on reproduction and neonatal toxicity in rats","volume":"27","author":"Lankas","year":"1989","journal-title":"Food chemical toxicology international journal published British Industrial Biological Research Association"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/epi.17511","article-title":"Is the antiparasitic drug ivermectin a suitable candidate for the treatment of epilepsy?","volume":"64","author":"Loscher","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/bs.apha.2017.01.003","article-title":"Glycine Receptor Drug Discovery","volume":"79","author":"Lynch","year":"2017","journal-title":"Adv. Pharm."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11375","article-title":"Anticonvulsant effects of ivermectin on pentylenetetrazole- and maximal electroshock-induced seizures in mice: the role of GABAergic system and K(ATP) channels","volume":"8","author":"Manavi","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bcp.2015.07.016","article-title":"Reducing inflammation and rescuing FTD-related behavioral deficits in progranulin-deficient mice with alpha7 nicotinic acetylcholine receptor agonists","volume":"97","author":"Minami","year":"2015","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2025.101360","article-title":"Glycine receptors: Structure, function, and therapeutic implications","volume":"103","author":"Mizzi","year":"2025","journal-title":"Mol. Asp. Med"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib32","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib33","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40263-023-01027-2","article-title":"New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System","volume":"37","author":"Perucca","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2023.01.004","article-title":"Biochemical mechanisms in pathogenesis of infantile epileptic spasm syndrome","volume":"105","author":"Riikonen","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib35","first-page":"111","article-title":"Ivermectin toxicity in young mice","volume":"46","author":"Skopets","year":"1996","journal-title":"Lab Anim. Sci."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib36","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s11259-007-0050-3","article-title":"The effect of ivermectin on convulsions in rats produced by lidocaine and strychnine","volume":"31","author":"Trailovic","year":"2007","journal-title":"Vet. Res Commun."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib37","doi-asserted-by":"crossref","unstructured":"Vel\u00ed\u0161ek, L., Jehle, K., Asche, S., Vel\u00ed\u0161kov\u00e1, J., 2007. Model of infantile spasms induced by N-methyl-D-aspartic acid in prenatally impaired brain. Ann Neurol 61, 109\u2013119..","DOI":"10.1002\/ana.21082"},{"key":"10.1016\/j.eplepsyres.2025.107712_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrneurol.2010.178","article-title":"The role of inflammation in epilepsy","volume":"7","author":"Vezzani","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.eplepsyres.2025.107712_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106027","article-title":"Neuroinflammation microenvironment sharpens seizure circuit","volume":"178","author":"Villasana-Salazar","year":"2023","journal-title":"Neurobiol. Dis."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012112500213X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012112500213X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:39:08Z","timestamp":1773815948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092012112500213X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":39,"alternative-id":["S092012112500213X"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107712","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term administration of EQU-001 (ivermectin) suppresses spasms in a rat model of infantile epileptic spasms syndrome","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107712"}}